Form 4: Neurocrine Biosciences CEO Kyle Gano Executes Stock Options and Sells Shares Under 10b5-1 Trading Plan
SEC Form 4
CEO Kyle Gano exercised stock options and sold shares of Neurocrine Biosciences (NBIX) common stock under pre-arranged 10b5-1 trading plans.
Summary
- On February 12, 2025, Neurocrine Biosciences CEO Kyle Gano exercised stock options to acquire 104,736 shares of common stock.
- On February 12, 2025, Mr. Gano was granted 19,628 Restricted Stock Units (RSUs).
- On February 13, 2025, Mr. Gano exercised RSUs to acquire 2,566 shares of common stock.
- On February 13, 2025, Mr. Gano sold 1,352 shares at a weighted average price of $116.8448, with prices ranging from $116.02 to $118.26.
- On February 13, 2025, Mr. Gano exercised RSUs to acquire 2,241 shares of common stock.
- On February 13, 2025, Mr. Gano sold 1,206 shares at a weighted average price of $116.8606, with prices ranging from $116.04 to $117.53.
- These transactions were executed under Rule 10b5-1 trading plans adopted on March 15, 2023, and June 14, 2024.
- Following these transactions, Mr. Gano directly owns 139,907 shares of Neurocrine Biosciences common stock, 104,736 stock options, 5,132 RSUs granted on February 13, 2023, and 6,725 RSUs granted on February 13, 2024.
Sentiment
Score: 5
Explanation: The sentiment is neutral. The document primarily reports routine stock transactions by the CEO under a pre-existing trading plan. There is no indication of unusual or concerning activity.
Positives
- The transactions were executed under pre-arranged 10b5-1 trading plans, which can reassure investors that the sales were not based on insider information.
Negatives
- The CEO selling shares, even under a 10b5-1 plan, could be perceived negatively by some investors.
Risks
- Executive stock sales can sometimes create short-term downward pressure on the stock price.
- Changes in executive compensation structures, such as the granting of RSUs, could impact future financial performance.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.
Industry Context
Executive stock transactions are common in the biotechnology industry and are often related to compensation packages. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects.
Comparison to Industry Standards
- Executive compensation practices, including the use of stock options and RSUs, are standard in the biotech industry to align management's interests with those of shareholders.
- Companies like Amgen (AMGN) and Gilead Sciences (GILD) also utilize similar equity-based compensation plans for their executives.
- The vesting schedules and terms of the RSUs appear to be within typical ranges for the industry.
Stakeholder Impact
- The stock sales could have a minor, short-term impact on shareholders due to potential price fluctuations.
- The equity-based compensation structure impacts employees by incentivizing performance and aligning interests with company success.
Key Dates
| Date | Description |
|---|---|
| March 15, 2023 | Date of adoption of the first Rule 10b5-1 trading plan. |
| February 13, 2023 | Date that 2,566 RSUs were granted to the Reporting Person. |
| June 14, 2024 | Date of adoption of the second Rule 10b5-1 trading plan. |
| February 13, 2024 | Date that 2,566 shares vested from the RSU granted on February 13, 2023. |
| February 12, 2025 | Date of stock option exercise and RSU grant. |
| February 13, 2025 | Date of stock sales and RSU exercises. |
| March 12, 2025 | Date when 1/48th of the shares underlying the option becomes vested and exercisable. |
| February 12, 2026 | Date when 1/4 of the Restricted Stock Units will vest. |
| February 13, 2026 | Date that 2,566 shares will vest from the RSU granted on February 13, 2023. |
| February 12, 2027 | Date when 1/4 of the Restricted Stock Units will vest. |
| February 13, 2027 | Date that 2,566 shares will vest from the RSU granted on February 13, 2023. |
| February 12, 2028 | Date when 1/4 of the Restricted Stock Units will vest. |
| February 12, 2029 | Date when 1/4 of the Restricted Stock Units will vest. |
| February 12, 2035 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.